45
Participants
Start Date
July 31, 2003
Primary Completion Date
August 31, 2007
Study Completion Date
May 31, 2010
irinotecan hydrochloride
Irinotecan will be given 250 mg/m\^2 through intravenous (IV) for 90 minutes on day 1 for every 21 days until tumor progression or unacceptable toxicity or other reason for discontinuation occurs
National Cancer Institute (NCI)
NIH
SWOG Cancer Research Network
NETWORK